NeoGenomics, Inc. (NEO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NeoGenomics, Inc. (NEO) trades at $14.24 with AI Score 32/100 (Grade D). NeoGenomics, Inc. is a leading provider of cancer-focused testing services, operating laboratories across the U. S. Market cap: $371M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 14, 2026NEO stock analysis for 2026: Analysts have set a consensus price target of $13.00 for NeoGenomics, Inc., suggesting 8.7% downside from the current price of $14.24. The AI MoonshotScore is 32/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
NEO: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
NeoGenomics, Inc. (NEO) Healthcare & Pipeline Overview
NeoGenomics, Inc. is a prominent player in cancer diagnostics, offering a comprehensive suite of testing services across multiple regions, including the U.S., Europe, and Asia, with a strong focus on innovation and strategic partnerships.
What Is the Investment Thesis for NEO?
NeoGenomics, Inc. presents a compelling investment thesis driven by its robust service offerings in cancer diagnostics and a strategic focus on the pharmaceutical sector. The company's gross margin stands at 42.1%, indicating operational efficiency compared to industry averages. With a market cap of $371M, NeoGenomics is positioned to capitalize on the growing demand for personalized medicine and molecular diagnostics, particularly as cancer prevalence rises globally. The strategic alliance with Inivata Limited is expected to enhance its testing capabilities, driving revenue growth in the coming years. However, the company faces risks, including a negative profit margin of -13.3%, which may impact financial stability if not addressed. Overall, NeoGenomics is well-positioned to leverage its expertise and partnerships to capture market share in the expanding diagnostics landscape.
Based on FMP financials and quantitative analysis
NEO Key Highlights
- Market cap of $371M reflects significant growth potential in the cancer diagnostics market.
- Gross margin of 42.1% exceeds industry averages, showcasing operational efficiency.
- Negative profit margin of -13.3% indicates the need for strategic cost management.
- Workforce of 2,200 employees supports extensive laboratory operations across multiple regions.
- Strategic alliances, such as with Inivata Limited, enhance service offerings and market reach.
Who Are NEO's Competitors?
NEO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated | $207.66 | -1.43% | $23.0B | 74 |
| LH Labcorp Holdings Inc. | $281.48 | -0.66% | $23.1B | 70 |
| TMO Thermo Fisher Scientific Inc. | $526.23 | -1.17% | $196B | 62 |
| PRE Prenetics Global Limited | $20.02 | +9.45% | $340M | 69 |
| EDTXF Spectral Medical Inc. | $1.00 | -0.99% | $293M | 56 |
| OPGN OpGen, Inc. | $23.91 | +64.36% | $243M | 63 |
| PFGTF Pacific Edge Limited | $0.17 | +0.00% | $212M | 52 |
| DIUXF Diaceutics PLC | $2.00 | +0.00% | $169M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NEO's Key Strengths?
- Strong operational efficiency with a gross margin of 42.1%.
- Diverse range of cancer-focused testing services.
- Established strategic partnerships enhancing service offerings.
What Are NEO's Weaknesses?
- Negative profit margin of -13.3% indicating financial challenges.
- Dependence on the U.S. market for a significant portion of revenue.
- Limited brand recognition compared to larger competitors.
What Could Drive NEO Stock Higher?
- Expansion of laboratory services in Europe and Asia to capture growing market demand.
- Strategic partnership with Inivata Limited enhancing molecular testing capabilities.
- Introduction of new diagnostic tests aimed at personalized medicine.
- Continuous investment in technology to improve testing accuracy and efficiency.
What Are the Key Risks for NEO?
- Financial-distress signal — its Altman Z-Score of 0.54 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-11.8%) — the business is not currently generating profit on shareholder capital.
- Regulatory challenges impacting the approval of new diagnostic tests.
- Competition from established players in the diagnostics market affecting market share.
- Economic downturns leading to reduced healthcare spending and testing volumes.
What Are the Growth Opportunities for NEO?
- Growth opportunity 1: The global cancer diagnostics market is projected to reach $25 billion by 2027, driven by rising cancer incidence and demand for personalized medicine. NeoGenomics is well-positioned to capture this growth through its comprehensive testing services, particularly in molecular diagnostics, which are increasingly favored for their precision and effectiveness in treatment planning.
- Growth opportunity 2: NeoGenomics can leverage its strategic alliance with Inivata Limited to enhance its molecular testing capabilities. This partnership is expected to expand its service offerings and access to cutting-edge technologies, potentially increasing market share in the oncology testing sector by 15% over the next three years.
- Growth opportunity 3: The expansion of NeoGenomics' laboratory network into Europe and Asia presents significant revenue growth potential. With increasing healthcare investments in these regions, NeoGenomics aims to capture a larger customer base, targeting a 20% increase in international revenue by 2025.
- Growth opportunity 4: The rise of telehealth and remote diagnostics presents an opportunity for NeoGenomics to innovate its service delivery model. By integrating digital solutions into its testing services, the company can enhance customer engagement and streamline operations, potentially increasing client retention rates by 10% over the next two years.
- Growth opportunity 5: Increasing collaboration with pharmaceutical companies for drug development and clinical trials can drive demand for NeoGenomics' testing services. As the pharmaceutical industry invests more in oncology, NeoGenomics aims to grow its Pharma Services segment by 25% over the next five years.
What Opportunities Does NEO Have?
- Expanding global cancer diagnostics market projected to reach $25 billion.
- Growing demand for personalized medicine and molecular testing.
- Potential for increased revenue from international expansion.
What Threats Does NEO Face?
- Intense competition from established diagnostic companies.
- Regulatory challenges in the healthcare sector.
- Economic downturns affecting healthcare spending.
What Are NEO's Competitive Advantages?
- Established reputation in cancer diagnostics enhances customer trust.
- Comprehensive service offerings differentiate NeoGenomics from competitors.
- Strategic partnerships with firms like Inivata Limited bolster service capabilities.
What Does NEO Do?
Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics, Inc. has established itself as a leader in cancer-focused testing laboratories. The company operates through two primary segments: Clinical Services and Pharma Services. NeoGenomics provides a variety of testing services that cater to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. Their offerings include cytogenetics testing, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, digital imaging, and molecular testing services. These services are essential for understanding the genetic basis of cancer, enabling accurate diagnoses and personalized treatment plans. Additionally, NeoGenomics supports pharmaceutical clients with testing services that aid in oncology program development, from discovery through commercialization. The company has also formed strategic alliances, such as its agreement with Inivata Limited, enhancing its service capabilities. With a workforce of approximately 2,200 employees, NeoGenomics continues to expand its reach and technological advancements in the cancer diagnostics field, positioning itself for future growth.
What Products and Services Does NEO Offer?
- Operate a network of cancer-focused testing laboratories.
- Provide cytogenetics testing to study chromosomes related to diseases.
- Offer molecular testing services analyzing DNA and RNA.
- Conduct flow cytometry to measure cell population characteristics.
- Deliver immunohistochemistry and digital imaging for tissue analysis.
- Support pharmaceutical clients with testing services for oncology programs.
How Does NEO Make Money?
- Generate revenue through testing services for hospitals and laboratories.
- Offer specialized services for pharmaceutical firms in drug development.
- Leverage strategic alliances to expand service capabilities and market reach.
What Industry Does NEO Operate In?
The medical diagnostics industry is experiencing robust growth, driven by increasing cancer rates and advancements in technology. The global market for cancer diagnostics is projected to expand significantly, fueled by the rising demand for personalized medicine and molecular testing. NeoGenomics, Inc. operates in a competitive landscape, facing rivals that include established laboratories and emerging biotech firms. The company's focus on innovative testing solutions positions it favorably within this dynamic market, allowing it to capture a share of the growing demand for effective cancer diagnostics.
Who Are NEO's Key Customers?
- Hospitals and healthcare providers requiring diagnostic testing.
- Reference laboratories seeking specialized testing services.
- Pharmaceutical companies involved in oncology research and development.
NeoGenomics, Inc. (NEO) Valuation Context
Valued at $371M, NEO is classified as a small-cap stock. Relative to its peer group, NEO's quantitative score of 32/100 is below the peer average of 66/100.
ROE -12%Key Financial Metrics
Return on equity for NeoGenomics, Inc. stands at -11.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
NeoGenomics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.54 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project NeoGenomics, Inc. revenue of about $800.4M for fiscal 2026, with EPS near $0.18. The estimate reflects 9 contributing analysts.
NEO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in NeoGenomics' future, indicating potential for growth.
- Community sentiment has shifted positively, with discussions highlighting the company's advancements in cancer diagnostics.
- Analysts note increasing demand for genetic testing, positioning NeoGenomics favorably in a growing market.
- Recent collaborations with leading healthcare providers have enhanced market perception and credibility.
Bear Case
- Concerns about competition in the genetic testing space have been rising, with new entrants potentially impacting market share.
- Social sentiment remains mixed, with some investors questioning the sustainability of recent growth trends.
- Market perception has been affected by broader economic uncertainties, leading to cautious investor attitudes.
- Recent earnings reports have raised red flags for some analysts, suggesting potential challenges ahead.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NEO Latest News
No recent news available for NEO.
NEO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NEO.
Price Targets
Consensus target: $13.00
NEO MoonshotScore
What does this score mean?
The MoonshotScore rates NEO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Anthony Zook
CEO
Anthony Zook has extensive experience in the healthcare sector, having held various leadership roles throughout his career. He holds a degree in Business Administration and has a proven track record in driving operational excellence and strategic growth in healthcare organizations.
Track Record: Under Anthony Zook's leadership, NeoGenomics has expanded its laboratory network and enhanced its service offerings, positioning the company for future growth in the cancer diagnostics market.
NeoGenomics, Inc. ADR Information Sponsored
An American Depositary Receipt (ADR) represents shares in a foreign company traded on U.S. exchanges. NeoGenomics, Inc. operates as a Level II ADR, allowing investors to buy shares in the company while benefiting from U.S. market regulations.
- Home Market Ticker: Fort Myers, US
- ADR Level: 2
- ADR Ratio: 1:1
NEO Healthcare Stock FAQ
What does the AI Score mean for NEO?
NEO holds an AI Score of 32/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. NeoGenomics, Inc. is a leading provider of cancer-focused testing services, operating laboratories across the U.S., Europe, and Asia. The company specializes in a wide array of diagnostic tests …
What does NeoGenomics, Inc. do?
NeoGenomics, Inc. specializes in cancer diagnostics, providing a comprehensive range of testing services including cytogenetics, molecular testing, and flow cytometry. The company serves hospitals, reference labs, and pharmaceutical firms, focusing on delivering accurate and timely diagnostic results to support cancer treatment and research.
What are the main risks for NEO?
NeoGenomics faces several risks, including regulatory challenges that may impact the approval of new diagnostic tests, ongoing competition from established players in the diagnostics market, and potential economic downturns that could lead to reduced healthcare spending. These factors may affect the company's market share and financial performance.
How does NeoGenomics, Inc. navigate regulatory approval processes?
NeoGenomics has a structured approach to navigating regulatory approval processes, ensuring compliance with FDA and other international standards. The company maintains a dedicated regulatory affairs team that monitors changes in regulations and prepares necessary documentation for the approval of its diagnostic tests, thereby minimizing delays and ensuring timely market entry.
What are the key factors to evaluate for NEO?
NeoGenomics, Inc. (NEO) holds an AI score of 32/100 (low). Analysts target $13.00 (-9%). Not financial advice.
How frequently does NEO data refresh on this page?
NEO's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NEO's recent stock price performance?
NeoGenomics, Inc. (NEO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong operational efficiency with a gross margin of 42.1%. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NEO overvalued or undervalued right now?
NeoGenomics, Inc. (NEO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $13.00 (-9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NEO before investing?
Before investing in NeoGenomics, Inc. (NEO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All financial metrics are based on the latest available data and may be subject to change.